Core Viewpoint - A securities fraud class action lawsuit has been filed against uniQure N.V. for misleading investors regarding its gene therapy drug AMT-130 during the specified Class Period [2][4][5]. Company Overview - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, particularly Huntington's disease (HD) [4]. - The company's leading drug candidate is AMT-130, aimed at slowing the progression of HD [4]. Lawsuit Details - The lawsuit, titled Scocco v. uniQure N.V., was filed in the United States District Court for the Southern District of New York [2]. - The Class Period for the lawsuit is defined as September 24, 2025, to October 31, 2025 [7]. - Investors who purchased shares during this period may seek to serve as lead plaintiffs by April 13, 2026 [3][9]. Allegations - The complaint alleges that uniQure made materially false and misleading statements regarding its Phase I/II clinical trials and the timeline for its Biologics License Application (BLA) submission to the FDA [5]. - Specific allegations include: 1. The design of the Pivotal Study was not fully approved by the FDA [5]. 2. The likelihood of needing to delay the BLA timeline was downplayed [5]. 3. Statements about the company's business and prospects lacked a reasonable basis [5]. Impact on Share Price - On November 3, 2025, uniQure's share price dropped by $33.40, or over 49%, from $67.69 to $34.29 following the revelation that the FDA did not agree with the adequacy of the data for BLA submission [6][8].

Core Viewpoint - A class action lawsuit has been filed against Oracle Corporation for alleged misleading statements regarding its AI infrastructure strategy and its impact on capital expenditures and financial health during the Class Period from June 12, 2025, to December 16, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Oracle's AI infrastructure strategy would lead to significant increases in capital expenditures without corresponding near-term revenue growth [5]. - It alleges that the increased spending poses serious risks to Oracle's debt, credit rating, free cash flow, and project funding capabilities [5]. - The lawsuit asserts that the representations made by Oracle regarding its business and prospects were materially false and misleading, resulting in investor damages when the true information became public [5]. Group 2: Participation Information - Investors who purchased Oracle common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent the interests of other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm specializes in securities class actions and has a strong track record, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].

Core Viewpoint - A class action lawsuit has been filed against PayPal Holdings, Inc. for allegedly providing misleading information regarding its financial targets and growth potential during the specified Class Period from February 25, 2025, to February 2, 2026 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that PayPal's management provided overly optimistic statements about the company's growth potential and its ability to execute on these targets, while concealing adverse facts about the salesforce's readiness [5]. - Investors who purchased PayPal common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by April 20, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 alone [4]. - The firm has been recognized for its success in securities class action settlements and has consistently ranked among the top firms in this area since 2013 [4].

Core Viewpoint - Gold has outperformed the S&P 500 Index for seven consecutive months, marking the longest streak since February 2008, a period just before the global financial crisis escalated [1][9]. Group 1: Historical Context - In early 2008, the financial crisis was not fully recognized, with Lehman Brothers' collapse occurring later that year and equity markets still reflecting a sense of stability [2][6]. - The narrative at that time was focused on a "housing problem," with investors believing that the issues were isolated to subprime mortgages and that major banks were adequately capitalized [6][8]. - Gold's performance in early 2008 indicated underlying market stress that was not yet apparent to most investors [4][11]. Group 2: Current Market Analysis - The current market environment lacks visible signs of a housing crash or banking panic, yet gold is again outperforming equities similarly to 2008 [9][11]. - This raises questions about what the market may be hedging against, as gold has historically recognized fragility before broader narratives catch up [11][12]. - The software sector may represent a potential fault line in 2026, drawing parallels to past market conditions where significant downturns were preceded by unnoticed vulnerabilities [14].

Core Points - A securities fraud class action lawsuit has been filed against CoreWeave, Inc. (NASDAQ: CRWV) for alleged material misstatements and omissions regarding the company's ability to meet customer demand for its services [1][1] - The class period for the lawsuit is from March 28, 2025, to December 15, 2025, with a lead plaintiff deadline set for March 13, 2026 [1][1] - The complaint alleges that CoreWeave overstated its ability to meet customer demand, understated reliance on a single third-party data center supplier, misrepresented financial risks associated with this dependency, and made materially false public statements leading to inaccurate revenue expectations [1][1][1] Investor Actions - Investors who purchased CoreWeave securities during the class period are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options and a free case evaluation [1][1] - Investors can choose to retain counsel or take no action, and they have the option to file to be a lead plaintiff by the specified deadline [1][1] About the Law Firm - Kessler Topaz Meltzer & Check, LLP is a prominent U.S. plaintiff-side law firm specializing in securities-fraud class actions and has recovered over $25 billion for clients [1][1] - The firm has received numerous accolades for its work in securities litigation and operates globally with offices in Pennsylvania and California [1][1]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Corcept Therapeutics Incorporated common stock during the specified Class Period, indicating potential legal issues surrounding the company's New Drug Application for relacorilant [1][5]. Group 1: Lawsuit Details - The class action lawsuit is focused on the period between October 31, 2024, and December 30, 2025, during which Corcept allegedly misrepresented the status of its NDA for relacorilant, claiming strong support from clinical trials while the FDA had raised concerns about the evidence [1][5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees, as compensation may be available through a contingency fee arrangement [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a notable $438 million secured for investors in 2019 [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the firm directly for more information [3][6]. - It is noted that no class has been certified yet, and investors have the option to select their counsel or remain absent from the class at this stage [7].

Tesla (TSLA 1.52%) is expected to deliver critical crash data on potential full-self driving (FSD) traffic violations to the National Highway Traffic Safety Administration (NHTSA) on or before March 9.The data is certainly meaningful, as it's part of an NHTSA investigation. Moreover, given that Tesla has reported 14 incidents involving its robotaxis (using unsupervised FSD) since their inception in June 2025, the company and its robotaxi rollout appear under significant pressure. But just how bad is it for ...

D-Wave Quantum (QBTS 6.93%) stock managed to close out last week's trading solidly in the green despite a significant pullback in Friday's session. The company's share price ended the stretch up 4%. Meanwhile, the S&P 500 fell 0.4% in the week, and the Nasdaq Composite fell 1%. D-Wave Quantum stock saw gains in the lead-up to its fourth-quarter report. The stock also initially saw gains following its Q4 report, but sell-offs gained steam after the release. D-Wave's Q4 results missed the mark, but investors ...

Group 1 - The Rosen Law Firm is reminding sellers of Masonite International Corporation common stock about a class action lawsuit with a lead plaintiff deadline of April 7, 2026 [1][2] - Investors who sold Masonite common stock between June 5, 2023, and February 8, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][4] - The lawsuit alleges that defendants made material omissions and misrepresentations regarding Owens Corning's offers to purchase Masonite's stock at significant premiums, which could have indicated a higher value for Masonite's stock [4] Group 2 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased BlackRock TCP Capital Corp. securities during the specified class period of the upcoming lead plaintiff deadline on April 6, 2026 [1]. Group 1: Class Action Details - Investors who bought BlackRock TCP securities between November 6, 2024, and January 23, 2026, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the court by April 6, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4]. Group 3: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements regarding BlackRock TCP's business and failed to disclose adverse facts, including issues with investment valuations and portfolio restructuring [5]. - It is claimed that BlackRock TCP's unrealized losses were understated and net asset value was overstated, leading to misleading positive statements about the company's prospects [5].